Harpoon Therapeutics amends Series A Preferred Stock certificate to reflect 1-for-10 reverse split

Harpoon Therapeutics, Inc.

Filed Certificate of Amendment on January 26, 2024, adjusting Series A Preferred Stock for the 1-for-10 reverse stock split effective September 1, 2023.
Amendment is administrative; no change to preferred stock rights, preferences, or limitations.
Reverse stock split was previously completed; this filing updates the preferred stock certificate accordingly.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Harpoon Therapeutics, Inc.: Filed Certificate of Amendment to Certificate of Designation of Series A Preferred Stock to reflect a one-for-ten reverse stock split of common stock effected September 1, 2023 (effective 2024-01-26).

Change: charter amendment
Effective: 2024-01-26

Exact text from the filing

On January 26, 2024, Harpoon Therapeutics, Inc. (the “Company”) filed a Certificate of Amendment to its Certificate of Designation of Preferences, Rights and Limitations of 8.000% Series A Redeemable Preferred Stock (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware to reflect the one-for-ten reverse stock split of the Company’s common stock effected by the Company on September 1, 2023.

View on SEC.gov

Browse all governance changes →

Source: SEC EDGAR

accession 0001193125-24-018159

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.